The objective of this clinical study is to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of SV003 in healthy subjects.
Body Mass Index (BMI): 18.5 ≤ Chinese participants ≤ 30 kg/m², 18.5 ≤ Caucasian participants ≤ 32 kg/m²; additionally, male participants must have a body weight ≥ 50 kg, and female participants ≥ 45 kg;
Healthy status: No evidence of active or chronic diseases in participants;
Ability to participate in the study, willingness to provide written informed consent, and compliance with study requirements.
Subjects with a history of chronic diseases or currently presenting with clinically significant systemic diseases;
Subjects who have experienced a serious disease within 1 month prior to drug administration, or with any disease that may relapse immediately during or after the study;
Subjects with designated examination results reaching a specified value;
Subjects with abnormal laboratory test results deemed clinically significant by the investigator;
Sequential
SV003
DrugSV003：Single-dose
Placebo
DrugPlacebo ： Single-dose
Incidence of Treatment-Emergent Adverse Events
Adverse event type, incidence, duration
Peak Plasma Concentration (Cmax)
PK (Pharmacokinetics)
Peak time（Tmax）
PK (Pharmacokinetics)
Area under the plasma concentration versus time curve (AUC)
PK (Pharmacokinetics)
half-life（T1/2）
PK (Pharmacokinetics)
Click on the lead sponsor to view all of their trials.
